Skip to main content
Jinyu Bio-Technology Co.,Ltd. logo

Jinyu Bio-Technology Co.,Ltd. — Investor Relations & Filings

Ticker · 600201 ISIN · CNE000000Y37 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,778 across all filing types
Latest filing 2016-02-24 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 600201

About Jinyu Bio-Technology Co.,Ltd.

http://jinyubiotech.com/

Jinyu Bio-Technology Co., Ltd. focuses on the research, development, and manufacturing of veterinary biological products and pharmaceuticals. The company is a prominent supplier of animal vaccines, particularly specializing in Foot-and-Mouth Disease (FMD) vaccines, brucellosis vaccines, and solutions for swine and poultry diseases. It utilizes advanced biotechnology platforms, including large-scale suspension culture and high-efficiency purification processes, to produce high-titer, high-purity biologicals. The organization operates sophisticated research facilities and Biosafety Level 3 (P3) laboratories to support the development of diagnostic reagents and preventive treatments. Its operations center on enhancing animal health through scientific innovation, providing comprehensive disease control strategies for the global livestock industry and large-scale agricultural operations.

Recent filings

Filing Released Lang Actions
独立董事关于调整公司2015年度非公开发行股票方案中部分事项的独立意见
Capital/Financing Update Classification · 95% confidence The document is an independent director's opinion on adjustments to a 2015 non-public stock issuance plan by the company. It references relevant laws and regulations, discusses the issuance price, quantity, and validity period, and confirms compliance with legal requirements. The document is a formal opinion related to a capital raising activity (non-public stock issuance). It does not contain financial statements or detailed financial data but rather an opinion on a financing plan adjustment. The document length is short (1021 characters), and it is not a full report but an opinion related to capital/financing activities. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2016-02-24 Chinese
关于2015年度非公开发行股票募集资金使用的可行性分析（修订稿）
Capital/Financing Update Classification · 95% confidence The document is a detailed feasibility analysis report regarding the use of funds raised from a non-public stock issuance by 金宇生物技术股份有限公司. It discusses the investment plan, project background, market and policy environment, technical and management conditions, and financial impact. The content focuses on capital raising and the use of proceeds for a specific project, which aligns with a Capital/Financing Update. The document is not an annual or interim financial report, nor is it a regulatory announcement or a simple notice. It contains substantive information about the capital raising and investment plan, making it a Capital/Financing Update (CAP). The document length (6812 characters) supports it being a full report rather than a brief announcement.
2016-02-24 Chinese
关于召开2016年第一次临时股东大会的通知
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a detailed notice about convening the 2016 first extraordinary general meeting of shareholders for 金宇生物技术股份有限公司. It includes information about the meeting date, voting methods (including online voting), agenda items to be discussed and voted on, registration procedures, and proxy authorization forms. The content focuses on the announcement and procedural details of the shareholders meeting rather than the results of the meeting or the actual voting outcomes. There is no indication that this document contains the voting results or a summary of the meeting outcomes. Therefore, it is best classified as a Proxy Solicitation & Information Statement (PSI), which typically includes materials sent to shareholders to provide information and request votes for meetings.
2016-02-24 Chinese
2015年度非公开发行股票预案（修订稿）
Capital/Financing Update Classification · 100% confidence The document is titled as a "2015年度非公开发行股票预案（修订稿）" which translates to "2015 Annual Non-public Stock Issuance Proposal (Revised Draft)". It is a detailed plan regarding a non-public issuance of shares by the company 金宇生物技术股份有限公司. The content includes the background, purpose, issuance scheme, pricing, number of shares, use of proceeds, impact on control, and approval procedures. It is a comprehensive proposal document related to capital raising through a non-public stock issuance. There is no indication that this is an announcement of a report or a certification. The document is lengthy (15,000 characters) and contains substantive details about the capital raising plan. Therefore, it fits the category of a Capital/Financing Update (CAP).
2016-02-24 Chinese
第八届监事会第二十一次会议决议公告
Capital/Financing Update Classification · 95% confidence The document is a formal announcement of resolutions passed at a supervisory board meeting of a company regarding adjustments to a non-public stock issuance plan and related matters. It includes voting results and references to further detailed announcements on the stock issuance plan and feasibility analysis. The document is short (1126 characters) and primarily serves as a meeting resolution announcement rather than a full report or detailed financial disclosure. It does not contain financial statements or detailed financial data. The content focuses on board decisions about capital raising activities, specifically non-public stock issuance, which aligns with capital/financing updates. Therefore, the document is best classified as a Capital/Financing Update (CAP).
2016-02-24 Chinese
第八届董事会第二十二次会议决议公告
Board/Management Information Classification · 95% confidence The document is a board meeting resolution announcement from 金宇生物技术股份有限公司 (Jinyu Biotechnology Co., Ltd.) regarding approval of proposals related to a non-public stock issuance plan. It includes voting results from the board of directors meeting and mentions that the proposals will be submitted to a shareholders meeting. The document does not contain financial statements or detailed financial data, but rather decisions and approvals by the board. It is not an annual or interim report, nor an earnings release. It is not a proxy solicitation or voting results announcement from shareholders, but a board resolution announcement. Therefore, it fits best under Board/Management Information (MANG) as it relates to board decisions and approvals on financing matters.
2016-02-24 Chinese

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.